40
Participants
Start Date
February 28, 2014
Primary Completion Date
February 1, 2019
Study Completion Date
February 28, 2019
T-Cell replete haplo-transplant
Infusion of haploidentical related donor peripheral blood stem cells following myeloablative conditioning (fludarabine 200 mg/m2, busulfan 12.8 mg/kg and total body irradiation (TBI) 400 centigray -or- fludarabine 200 mg/m2, busulfan 9.6 mg/kg). GVHD prophylaxis will be with cyclophosphamide 50 mg/kg/day x 2 on days 3 \& 4, mycophenolate mofetil 1 gm p.o. bid days 5 - 35 and tacrolimus (5-15 ug/ml) days 5 - 100.
Foothills Medical Center / Tom Baker Cancer Center, Calgary
Health Sciences Center, Winnipeg
Ottawa General Hospital, Ottawa
McGill University Health Centre, Montreal
Royal University Hospital, Saskatoon
The Canadian Blood and Marrow Transplant Group
NETWORK
University of Calgary
OTHER